Pages that link to "Item:Q4489920"

The following pages link to The validation of surrogate endpoints in meta-analyses of randomized experiments (Q4489920):

Displaying 45 items.

• Choice of units of analysis and modeling strategies in multilevel hierarchical models (Q957034) (← links)
• Using earlier measures in a longitudinal sequence as a potential surrogate for a later one (Q962388) (← links)
• Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS (Q1020068) (← links)
• Exploring and validating surrogate endpoints in colorectal cancer (Q1029801) (← links)
• Center-within-trial versus trial-level evaluation of surrogate endpoints (Q1623614) (← links)
• Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials (Q1658329) (← links)
• The evaluation of surrogate endpoints. (Q1773294) (← links)
• An efficient algorithm to assess multivariate surrogate endpoints in a causal inference framework (Q2143008) (← links)
• Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption (Q2170431) (← links)
• Linear increment in efficiency with the inclusion of surrogate endpoint (Q2339530) (← links)
• Simplified modeling strategies for surrogate validation with multivariate failure-time data (Q2445595) (← links)
• The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials (Q2475730) (← links)
• Statistical evaluation of surrogate endpoints with examples from cancer clinical trials (Q2792764) (← links)
• Design and estimation for evaluating principal surrogate markers in vaccine trials (Q2846433) (← links)
• A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials (Q2893404) (← links)
• Comparing biomarkers as principal surrogate endpoints (Q2893405) (← links)
• Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling (Q2894010) (← links)
• Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time (Q2894011) (← links)
• Bayesian adaptive trial design for a newly validated surrogate endpoint (Q2894012) (← links)
• Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials (Q3076045) (← links)
• The Evaluation of Multiple Surrogate Endpoints (Q3078684) (← links)
• Principal Stratification in Causal Inference (Q3078899) (← links)
• A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker (Q3079026) (← links)
• A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint (Q3434121) (← links)
• Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints (Q3445296) (← links)
• Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach (Q3445321) (← links)
• On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints (Q3465713) (← links)
• A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials (Q3576929) (← links)
• On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm (Q3637000) (← links)
• Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics (Q4430351) (← links)
• Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes (Q5121917) (← links)
• Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements (Q5122424) (← links)
• Advances in medical statistics arising from the AIDS epidemic (Q5424106) (← links)
• Surrogate Marker Evaluation from an Information Theory Perspective (Q5427415) (← links)
• Pairwise Fitting of Mixed Models for the Joint Modeling of Multivariate Longitudinal Profiles (Q5492080) (← links)
• Discussion on ``Surrogate measures and consistent surrogates'' (Q5891277) (← links)
• Confidence intervals and statistical power of the ``Validation'' ratio for surrogate or intermediate endpoints (Q5939496) (← links)
• A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials (Q6071311) (← links)
• Robust Approach to Combining Multiple Markers to Improve Surrogacy (Q6079767) (← links)
• Assurance in vaccine efficacy clinical trial design based on immunological responses (Q6085899) (← links)
• One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints (Q6624663) (← links)
• Bivariate network meta-analysis for surrogate endpoint evaluation (Q6624702) (← links)
• Predictive probability of success using surrogate endpoints (Q6625585) (← links)
• Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data (Q6627523) (← links)
• On the relationship between association and surrogacy when both the surrogate and true endpoint are binary outcomes (Q6629840) (← links)